Structure via PubChem · Public domain (PubChem)
lenacapavir
Sign in to saveAlso known as Sunlenca
Lenacapavir, sold under the brand names Sunlenca among others, is an antiretroviral medication used to treat and prevent HIV/AIDS. It is taken by mouth or by subcutaneous injection. Lenacapavir is a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor.
Key facts
- Drug.N
- 7
- Drug.O
- 5
- Drug.S
- 2
- Drug.image
- Lenacapavir.svg
- Drug.image_class
- skin-invert-image
- Drug.caption
- Molecular structure of lenacapavir
- Drug.image2
- Lenacapavir 3D.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Sunlenca, Yeztugo, others
- Drug.MedlinePlus
- a623005
- Drug.DailyMedID
- Lenacapavir
- Drug.pregnancy_AU
- B1
- Drug.routes_of_administration
- By mouth, subcutaneous
- Drug.caption2
- 3D representation of a lenacapavir molecule
- Drug.class
- Capsid inhibitors
- Drug.ATC_prefix
- J05
- Drug.ATC_suffix
- AX31
- Drug.legal_AU
- S4
via Wikipedia infobox
Chemical data
- Formula
- C39H32ClF10N7O5S2
- Molecular weight
- 968.3 g/mol
- IUPAC name
- N-[(1S)-1-[3-[4-chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)indazol-7-yl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)-2-pyridinyl]-2-(3,5-difluorophenyl)ethyl]-2-[(2S,4R)-5,5-difluoro-9-(trifluoromethyl)-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetamide
- SMILES
- CC(C)(C#CC1=NC(=C(C=C1)C2=C3C(=C(C=C2)Cl)C(=NN3CC(F)(F)F)NS(=O)(=O)C)[C@H](CC4=CC(=CC(=C4)F)F)NC(=O)CN5C6=C([C@H]7C[C@H]7C6(F)F)C(=N5)C(F)(F)F)S(=O)(=O)C
- InChIKey
- BRYXUCLEHAUSDY-WEWMWRJBSA-N
- XLogP
- 6.4
- Polar surface area
- 175 Ų
- H-bond donors
- 2
- H-bond acceptors
- 19
- Formal charge
- 0
via PubChem
~10 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Mechanism of action
- History
- Society and culture
- Legal status
- Economics
- Research
- References
- External links
{{Infobox drug | image = Lenacapavir.svg | image_class = skin-invert-image | alt = | caption = Molecular structure of lenacapavir | image2 = Lenacapavir 3D.png | image_class2 = bg-transparent | pronounce = | tradename = Sunlenca, Yeztugo, others | Drugs.com = | MedlinePlus = a623005 | DailyMedID = Lenacapavir | pregnancy_AU = B1 | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth, subcutaneous | caption2 = 3D representation of a lenacapavir molecule | class = Capsid inhibitors | ATC_prefix = J05 | ATC_suffix = AX31
| legal_AU = S4 | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = Rx-only | legal_CA_comment = | legal_DE = | legal_DE_comment = | legal_NZ = | legal_NZ_comment = | legal_UK = | legal_UK_comment = | legal_US = Rx-only | legal_US_comment = | legal_EU = Rx-only | legal_EU_comment = | legal_UN = | legal_UN_comment = | legal_status = | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion = | CAS_number = 2189684-44-2 | CAS_supplemental = | PubChem = | IUPHAR_ligand = | DrugBank = DB15673 | ChemSpiderID = 81367881 | UNII = A9A0O6FB4H | KEGG = D12161 | KEGG2 = D12162 | ChEBI = | ChEMBL = 4594438 | NIAID_ChemDB = | PDB_ligand = QNG | synonyms = GS-CA2, GS-6207
Excerpted from Wikipedia’s “lenacapavir” article, available under the CC BY-SA 4.0 licence.